New research calls for a health equity lens in commercial tobacco product regulation

Innovation
Jul.19.2022

University of Minnesota School of Public Health Assistant Professor Dana Mowls Carroll co-authored a recent commentary in Preventive Medicine on how commercial tobacco policies contribute to inequities, including the unequal and unjust burden of tobacco-related disease and death among racialized populations.

The researchers explained that policies allow the continued sale of menthol cigarettes — especially via targeted marketing — that increase the risk of commercial tobacco use among Black or African American (B/AA) and Indigenous American adults. At the same time, policies banning e-cigarette flavors to prevent young people from starting to vape have received considerable attention. These policies disproportionately benefit white youth, whose  e-cigarette use is higher compared to B/AA youth. Although youth e-cigarette use prevention is critical, the level of support, urgency and publicity for banning e-cigarette flavors exceeds that for banning menthol cigarettes, furthering inequities in how regulation benefits various groups.

 

The writers assert that equitable opportunities for a healthy life can no longer be afterthoughts or secondary aims for policymakers, and call for a health equity lens in commercial tobacco product regulation and provide individual and system-level recommendations that put health equity at the forefront of regulation and research.

New research calls for a health equity lens in commercial tobacco product regulation

Their recommendations include:

The Food and Drug Administration — which regulates commercial tobacco products at the national level — should address health equity directly while evaluating regulations and prioritizing research that examines how regulations, or lack thereof, may increase or decrease commercial tobacco-related health inequities experienced by B/AA and Indigenous American groups.

Community engagement is critical and public health professionals must be prepared to do this well. This approach can be used to authentically engage with populations at greatest risk for tobacco-related disease and ensure their voices and wisdom are prioritized during policy development and implementation.

More B/AA and Indigenous American tobacco regulatory science researchers should be mentored, recruited and supported in their training.

This work must start with understanding the roots of inequities. All researchers must educate themselves about the cultural and historic contexts in which their academic and community institutions exist and their impacts on B/AA and Indigenous communities.

“Striving for the highest possible standard of health for all people means that we must educate ourselves on the true roots of inequities, particularly racism, and identify public health approaches and policies that are anti-racist,” said Carroll. “I am interested in how populations that bear the greatest smoking-related burdens benefit to a lesser extent from, or can even be harmed by, the implementation or lack of tobacco-related policies when compared with socially privileged populations.”

 

This research was supported by the National Institute on Drug Abuse of the National Institutes of Health (NIH), by the National Institute on Minority Health and Health Disparities of the NIH and the Center for Tobacco Products of the U.S. Food and Drug Administration. 

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23